Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | In-line → Underperform | Evercore ISI | |
| 8/9/2024 | $5.00 → $1.00 | Outperform → Market Perform | Leerink Partners |
| 7/3/2024 | $5.00 | Market Perform → Outperform | Leerink Partners |
| 4/2/2024 | $6.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 2/13/2024 | $23.00 → $7.00 | Outperform → Market Perform | Leerink Partners |
| 2/12/2024 | $25.00 → $7.00 | Outperform → In-line | Evercore ISI |
| 2/12/2024 | Outperform → Perform | Oppenheimer | |
| 2/12/2024 | Mkt Outperform → Mkt Perform | JMP Securities |
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)
Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform
Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously
Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the
AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all
Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease Extensive enabling NTM data provides potential path forward in M. abscessus lung disease Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging oncology portfolio Initiated start up activities for Phase 1 first in human study in healthy volunteers of AN2-502998, under development to treat chronic Chagas disease Topline data for standard-of-care melioidosis observational trial expected in 2Q25; Phase 2 study
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event is as follows: Citizens JMP Life Sciences Conference Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat on Wednesday, May 7, 2025 at 9:00 am ET, and members of management will be available for 1X1 meetings. A webcast can be accessed on the Investors se
Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first in human study of AN2-502998, under development for Chagas disease, to start mid-2025 in healthy volunteers Topline data for melioidosis observational trial expected in 2Q25; Phase 2 epetraborole study planned for 2H25 First oncology candidate(s) from boron chemistry platform on track to advance into development in 2H25 Cash, cash equivalents, and investments of $88.6 million at December 31, 2024 anticipated to fund operations through 2027 under current strategic plan AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering an
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)